p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8(+) T cell responses

PURPOSE: To conduct a Phase I trial of a Modified Vaccinia Ankara vaccine delivering wild type human p53 (p53MVA) in patients with refractory gastrointestinal cancers. EXPERIMENTAL DESIGN: Three patients were vaccinated with 1.0 × 10(8) pfu p53MVA followed by nine patients at 5.6 × 10(8) pfu. Toxici...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hardwick, Nicola R, Carrol, Mary, Kaltcheva, Teodora, Qian, Dajun, Lim, Dean, Leong, Lucille, Chu, Peiguo, Kim, Joseph, Chao, Joseph, Fakih, Marwan, Yen, Yun, Espenschied, Jonathan, Ellenhorn, Joshua D I, Diamond, Don J, Chung, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155000/
https://ncbi.nlm.nih.gov/pubmed/24987057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3361
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados